Century Therapeutics, Inc. IPSC
As ofNov 20, 2026, 11:57 AM EST
- YTD
- +20.60%
- 1 year
- +144.40%
5D -0.34 (-19.77%)
- Market cap
- 216.28M
- Revenue (ttm)
- 2.68M
- EPS (ttm)
- -0.64
- Shares out
- 85.03M
- Forward P/E
- -0.76
- YTD return
- +20.60%
- 1-year return
- +144.40%
- 50-day average
- 1.38
- 200-day average
- 2.38
- Volume
- 343.62K
- Avg volume
- 750.54K
- Open
- 1.22
- Previous close
- 1.32
- Day's range
- 1.19 – 1.22
- 52-week range
- 0.464 – 3.04
- Beta
- 1.42
- Analysts
- Buy
- Price target
- 9.67 (+705.6%)
Key statistics
- Enterprise value
- -49.98M
- Price / sales
- 32.31
- Price / book
- 0.44
- Revenue growth
- 434.50%
- Free cash flow
- -62.05M
- Total cash
- 198.11M
- Total debt
- 54.60M
- Return on equity
- -62.61%
- Short % of float
- 4.13%
Fundamental scorecard
3 of 25 checks passed on IPSC’s reported financials
3of 25 checks passed
- Value 0 of 5
- Growth 0 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2024 | Sep 1, 2024 | -0.46 | -0.37 | +0.09 | +19.57% |
| Aug 8, 2024 | Jun 1, 2024 | -0.50 | — | — | — |
| Aug 8, 2024 | Jun 1, 2024 | -0.50 | -0.38 | +0.12 | +24.00% |
| May 9, 2024 | Mar 1, 2024 | -0.50 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -0.50 | -0.45 | +0.05 | +10.00% |
| Mar 14, 2024 | Dec 1, 2023 | -0.56 | -0.49 | +0.07 | +12.50% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 7, 2024 | Chardan Capital | main | Buy | Buy |
| Nov 6, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Aug 15, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Jun 17, 2024 | Piper Sandler | main | Overweight | Overweight |
| Jun 4, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 10, 2024 | HC Wainwright & Co. | main | Buy | Buy |
About Century Therapeutics, Inc.
Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- centurytx.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on IPSC — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BORGES LUIS | Officer | Conversion of Exercise of derivative security | Apr 2, 2023 | 256,535 |
| CARR DOUGLAS | Officer | Sale | Nov 3, 2024 | 317,147 |
| CONN MORGAN PH.D. | Chief Financial Officer | Stock Award(Grant) | Oct 13, 2024 | 60,148 |
| COWAN CHAD | Officer | Stock Award(Grant) | Sep 30, 2024 | 221,503 |
| DIEM MICHAEL CRAIG | Chief Financial Officer | Stock Award(Grant) | May 14, 2023 | 274,296 |
| FARID ADRIENNE | Chief Operating Officer | Sale | Nov 3, 2024 | 135,130 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 6.36% | 5,410,361 | 5.52M | Sep 29, 2024 |
| VR Adviser, LLC | 6.34% | 5,389,259 | 5.50M | Sep 29, 2024 |
| Boxer Capital, LLC | 4.59% | 3,900,000 | 3.98M | Sep 29, 2024 |
| Casdin Capital, LLC | 3.78% | 3,212,316 | 3.28M | Sep 29, 2024 |
| Blackrock Inc. | 3.52% | 2,989,920 | 3.05M | Sep 29, 2024 |
| FMR, LLC | 2.97% | 2,521,511 | 2.57M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.55% | 1,314,621 | 1.34M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 1.21% | 1,026,978 | 1.05M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.92% | 785,571 | 801.28K | Sep 29, 2024 |
| Fidelity Growth Company Fund | 0.88% | 746,169 | 761.09K | Oct 30, 2024 |
| Fidelity Small Cap Index Fund | 0.56% | 477,391 | 486.94K | Aug 30, 2024 |
| Fidelity Growth Company K6 Fund | 0.52% | 445,272 | 454.18K | Oct 30, 2024 |
